2022
DOI: 10.3389/fonc.2022.903691
|View full text |Cite
|
Sign up to set email alerts
|

Presence of the GFI1-36N single nucleotide polymorphism enhances the response of MLL-AF9 leukemic cells to CDK4/6 inhibition

Abstract: The zinc finger protein Growth Factor Independence 1 (GFI1) acts as a transcriptional repressor regulating differentiation of myeloid and lymphoid cells. A single nucleotide polymorphism of GFI1, GFI1-36N, has a prevalence of 7% in healthy Caucasians and 15% in acute myeloid leukemia (AML) patients, hence most probably predisposing to AML. One reason for this is that GFI1-36N differs from the wildtype form GFI1-36S regarding its ability to induce epigenetic changes resulting in a derepression of oncogenes. Usi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 47 publications
0
1
0
Order By: Relevance
“…The fundamental reason for this inefficiency in patient screening lies in the lack of a clear understanding of how tumors respond to CDK4/6i-based therapies, leading to inconsistent patient stratification based on response outcomes. The current sensitivity screening methods mainly rely on surfacelevel characteristics, such as single gene analysis, scattered single nucleotide polymorphisms (SNPs) of pharmacogenomics, and simple association analysis such as genome-wide association studies (GWAS) [42][43][44] . However, these methods fall short in revealing the underlying systemic mechanisms of drug sensitivity.…”
Section: Introductionmentioning
confidence: 99%
“…The fundamental reason for this inefficiency in patient screening lies in the lack of a clear understanding of how tumors respond to CDK4/6i-based therapies, leading to inconsistent patient stratification based on response outcomes. The current sensitivity screening methods mainly rely on surfacelevel characteristics, such as single gene analysis, scattered single nucleotide polymorphisms (SNPs) of pharmacogenomics, and simple association analysis such as genome-wide association studies (GWAS) [42][43][44] . However, these methods fall short in revealing the underlying systemic mechanisms of drug sensitivity.…”
Section: Introductionmentioning
confidence: 99%